Helen Rochford-Brennan, a 72-year-old Irish woman living with Alzheimer’s, was first diagnosed at 57, with a more complete diagnosis following five years later. At the time, there were no life-enhancing medications, leaving her to face the grim reality of her brain’s gradual decline, enduring what she described as “many dark days.” “Imagine having a new […] Continue reading ->
Three African countries—Algeria, Cabo Verde, and Mauritius—have successfully eliminated malaria, but dozens more still face this deadly disease. Globally, only 44 countries have eradicated malaria. The question of whether the rest of Africa catch up was explored in the latest Global Health Matters podcast, hosted by Dr. Garry Aslanyan. To delve into this issue, Aslanyan […] Continue reading ->
Geneva, Switzerland—The 2024 World Cancer Congress opened Tuesday in Geneva, bringing together more than 2,000 delegates from more than 120 countries. Its convener said the congress underscores a global commitment to combating the growing burden of cancer. Hosted by the Union for International Cancer Control (UICC), the congress aims to foster collaboration amongst cancer and […] Continue reading ->
NAIROBI – Africa can harness community care, traditional health, exercise and digital tools to treat dementia as its population ages, according to experts on the second day of Nature’s “Future of Dementia in Africa” conference,. The conference, the first of its kind in Africa, was presented in conjunction with the Davos Alzheimer’s Collaborative and Aga […] Continue reading ->
NAIROBI, Kenya – Dementia is rapidly becoming a significant public health concern across the globe, with projections estimating 150 million people will be affected by 2050. “Dementia is a health, financial and social problem of almost unimaginable proportions,” said George Vradenburg, founding chairman of the board of the Davos Alzheimer’s Collaborative (DAC). “It may prove […] Continue reading ->
Eli Lilly’s Alzheimer’s therapy, donanemab, has received FDA approval, offering new hope for patients with early symptomatic Alzheimer’s disease. The newly approved treatment, branded Kisunla, is set to challenge existing therapies from Eisai and Biogen.  Clinical trials have shown Kisunla to be effective for individuals in the mild cognitive impairment or mild dementia stages of […] Continue reading ->